Payment overview · 2025
General Payments
$5,352.55
264 reported records · 41 companies
Healthcare provider profile · identity verified
Ryan Scott Conrad, M.D.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · MOORESVILLE, NC · NPI 1346289402
Verified facts
What the public records show
CMS Open Payments records show Ryan Scott Conrad, M.D. received $5,352.55 in general payments during 2025 across 264 reported records.
TG Therapeutics, Inc. accounted for 11.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 59 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Botox, Briviact, Gamunex-C, Nuedexta, Nuplazid, Nurtec Odt, Qulipta, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BOTOX as an associated drug or biological on 140321 records involving 30103 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Botox by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Ubrelvy by this doctor in 2024.
ACADIA Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUPLAZID as an associated drug or biological on 20845 records involving 6448 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Nuplazid by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 25 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Eliquis by this doctor in 2024.
Grifols USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Gamunex-C as an associated drug or biological on 3977 records involving 2134 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Gamunex-C by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MAYZENT as an associated drug or biological on 26 records involving 26 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Mayzent by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Nuedexta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Nurtec Odt by this doctor in 2024.
SK Life Science, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XCOPRI as an associated drug or biological on 1992 records involving 782 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Xcopri by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Briviact as an associated drug or biological on 13595 records involving 4444 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Briviact by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $632.51 | 11.8% | 18 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $598.61 | 11.2% | 57 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $529.50 | 9.9% | 21 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $339.26 | 6.3% | 13 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $333.15 | 6.2% | 21 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $260.34 | 4.9% | 13 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $259.09 | 4.8% | 7 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $249.52 | 4.7% | 10 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$242.64 | 4.5% | 14 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $204.91 | 3.8% | 11 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $175.43 | 3.3% | 9 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $137.05 | 2.6% | 8 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $121.01 | 2.3% | 4 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $113.79 | 2.1% | 6 | 2025 |
| Aucta Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $89.11 | 1.7% | 5 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $86.23 | 1.6% | 3 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $86.00 | 1.6% | 4 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $72.36 | 1.4% | 3 | 2025 |
| Impel Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $70.49 | 1.3% | 3 | 2025 |
| Avadel CNS Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $64.65 | 1.2% | 3 | 2025 |
| Sandoz Inc. | Unresolved — no canonical attribution shown | $61.30 | 1.1% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $56.17 | 1.1% | 2 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $53.22 | 1.0% | 3 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $49.82 | 0.9% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $39.07 | 0.7% | 2 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $38.15 | 0.7% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $36.92 | 0.7% | 2 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $35.30 | 0.7% | 2 | 2025 |
| TerSera Therapeutics LLC | Unresolved — no canonical attribution shown | $33.23 | 0.6% | 1 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$31.30 | 0.6% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $29.25 | 0.6% | 2 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $26.78 | 0.5% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $25.61 | 0.5% | 1 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $24.90 | 0.5% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $24.18 | 0.5% | 1 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $23.29 | 0.4% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.25 | 0.4% | 1 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $22.39 | 0.4% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $19.42 | 0.4% | 1 | 2025 |
| Kedrion Biopharma, Inc. | Unresolved — no canonical attribution shown | $18.89 | 0.3% | 1 | 2025 |
| Tanabe Pharma America, Inc. | Unresolved — no canonical attribution shown | $14.46 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $5,106.97 | 261 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $245.58 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $632.51 | 18 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $522.58 | 51 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $485.38 | 19 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $471.85 | 46 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $300.88 | 17 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $293.60 | 18 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $260.34 | 13 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $249.52 | 10 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $242.64 | 14 | 2025 |
Source payment records
|
|||||
| Zilbrysq Normalized: zilbrysq |
Drug | UCB, Inc. | $203.55 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $175.43 | 9 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $137.05 | 8 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $137.05 | 8 | 2025 |
Source payment records
|
|||||
| Mavenclad Normalized: mavenclad |
Drug | EMD Serono, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $121.01 | 4 | 2025 |
Source payment records
|
|||||
| Apokyn Normalized: apokyn |
Drug | MDD US Operations, LLC | $119.46 | 6 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $113.79 | 6 | 2025 |
Source payment records
|
|||||
| Motpoly XR Normalized: motpoly xr |
Drug | Aucta Pharmaceuticals, Inc. | $89.11 | 5 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $86.23 | 3 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $86.00 | 4 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $85.25 | 8 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $72.36 | 3 | 2025 |
Source payment records
|
|||||
| TRUDHESA Normalized: trudhesa |
Drug | Impel Pharmaceuticals LLC | $70.49 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $67.12 | 5 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $65.11 | 7 | 2025 |
Source payment records
|
|||||
| LUMRYZ Normalized: lumryz |
Drug | Avadel CNS Pharmaceuticals, LLC | $64.65 | 3 | 2025 |
Source payment records
|
|||||
| Tyruko Normalized: tyruko |
Biological | Sandoz Inc. | $61.30 | 2 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $56.48 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $49.82 | 2 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $47.37 | 2 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation | $38.15 | 2 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $36.92 | 2 | 2025 |
Source payment records
|
|||||
| EPIDIOLEX Normalized: epidiolex |
Drug | JAZZ PHARMACEUTICALS INC. | $35.57 | 2 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $35.30 | 2 | 2025 |
Source payment records
|
|||||
| Quzyttir Normalized: quzyttir |
Drug | TerSera Therapeutics LLC | $33.23 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $25.61 | 1 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $25.10 | 1 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $24.90 | 1 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Drug | PFIZER INC. | $23.56 | 1 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | PFIZER INC. | $23.56 | 1 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $23.29 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $23.25 | 1 | 2025 |
Source payment records
|
|||||
| Gamunex-C Normalized: gamunex c |
Biological | Grifols USA, LLC | $22.39 | 1 | 2025 |
Source payment records
|
|||||
| EMGALITY Normalized: emgality |
Drug | Lilly USA, LLC | $21.68 | 1 | 2025 |
Source payment records
|
|||||
| NUEDEXTA Normalized: nuedexta |
Drug | Otsuka America Pharmaceutical, Inc. | $21.32 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $19.94 | 1 | 2025 |
Source payment records
|
|||||
| Xadago Normalized: xadago |
Drug | MDD US Operations, LLC | $19.94 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $19.42 | 1 | 2025 |
Source payment records
|
|||||
| Albuked Normalized: albuked |
Biological | Kedrion Biopharma, Inc. | $18.89 | 1 | 2025 |
Source payment records
|
|||||
| GAMMAKED Normalized: gammaked |
Biological | Kedrion Biopharma, Inc. | $18.89 | 1 | 2025 |
Source payment records
|
|||||
| KEDRAB Normalized: kedrab |
Biological | Kedrion Biopharma, Inc. | $18.89 | 1 | 2025 |
Source payment records
|
|||||
| KOATE Normalized: koate |
Biological | Kedrion Biopharma, Inc. | $18.89 | 1 | 2025 |
Source payment records
|
|||||
| RhoGAM Ultra-Filtered PLUS Normalized: rhogam ultra filtered plus |
Biological | Kedrion Biopharma, Inc. | $18.89 | 1 | 2025 |
Source payment records
|
|||||
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $17.65 | 1 | 2025 |
Source payment records
|
|||||
| ZEMBRACE SYMTOUCH Normalized: zembrace symtouch |
Drug | Tonix Medicines, Inc. | $15.19 | 1 | 2025 |
Source payment records
|
|||||
| Radicava Normalized: radicava |
Drug | Tanabe Pharma America, Inc. | $14.46 | 1 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $14.12 | 2 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $14.06 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $13.97 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BOTOX botox |
2025 | Botox | 2024 | 40 | exact normalized | Medicare Part D |
| Briviact briviact |
2025 | Briviact | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Gamunex-C gamunex c |
2025 | Gamunex-C | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NUEDEXTA nuedexta |
2025 | Nuedexta | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NUPLAZID nuplazid |
2025 | Nuplazid | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 55 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | BOTOX open payments reported associated product |
CMS Open Payments — General Payments 140321 supporting records · 30103 recipient NPIs · example record 1201352642 |
Botox · 2024 Exact normalized brand match · 1 Part D row |
40 | 15 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ACADIA Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | NUPLAZID open payments reported associated product |
CMS Open Payments — General Payments 20845 supporting records · 6448 recipient NPIs · example record 1247763852 |
Nuplazid · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 25 supporting records · 24 recipient NPIs · example record 1184385048 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Grifols USA, LLC Exact reporting entity; no affiliate inference |
2025 | Gamunex-C open payments reported associated product |
CMS Open Payments — General Payments 3977 supporting records · 2134 recipient NPIs · example record 1249529381 |
Gamunex-C · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | MAYZENT open payments reported associated product |
CMS Open Payments — General Payments 26 supporting records · 26 recipient NPIs · example record 1200006493 |
Mayzent · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
| SK Life Science, Inc. Exact reporting entity; no affiliate inference |
2025 | XCOPRI open payments reported associated product |
CMS Open Payments — General Payments 1992 supporting records · 782 recipient NPIs · example record 1252276115 |
Xcopri · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Briviact open payments reported associated product |
CMS Open Payments — General Payments 13595 supporting records · 4444 recipient NPIs · example record 1224348489 |
Briviact · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 351 | 62 |
| Donepezil Hcl | Donepezil Hcl | 265 | 61 |
| Alprazolam | Alprazolam | 187 | 26 |
| Pregabalin | Pregabalin | 173 | 35 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 170 | 46 |
| Clonazepam | Clonazepam | 150 | 30 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 146 | 35 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 131 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 129 | 38 |
| Baclofen | Baclofen | 123 | 33 |
| Trazodone Hcl | Trazodone Hcl | 119 | 28 |
| Oxycodone Hcl | Oxycodone Hcl | 114 | 24 |
| Topiramate | Topiramate | 110 | 33 |
| Memantine Hcl | Memantine Hcl | 102 | 27 |
| Diazepam | Diazepam | 101 | 17 |
| Lorazepam | Lorazepam | 101 | 32 |
| Levetiracetam | Levetiracetam | 97 | 23 |
| Tizanidine Hcl | Tizanidine Hcl | 97 | 21 |
| Tramadol Hcl | Tramadol Hcl | 87 | 20 |
| Lacosamide | Lacosamide | 78 | 12 |
| Omeprazole | Omeprazole | 76 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 72 | 15 |
| Meloxicam | Meloxicam | 71 | 19 |
| Amitriptyline Hcl | Amitriptyline Hcl | 70 | 15 |
| Propranolol Hcl | Propranolol Hcl | 67 | 13 |
| Bupropion Xl | Bupropion Hcl | 65 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 65 | 13 |
| Lamotrigine | Lamotrigine | 61 | 12 |
| Nurtec Odt | Rimegepant Sulfate | 55 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 51 | suppressed |
| Mirtazapine | Mirtazapine | 48 | 16 |
| Memantine Hcl Er | Memantine Hcl | 47 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 47 | 12 |
| Methylphenidate Hcl | Methylphenidate Hcl | 43 | 15 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 42 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 42 | 15 |
| Botox | Onabotulinumtoxina | 40 | 15 |
| Carbamazepine Er | Carbamazepine | 37 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 37 | suppressed |
| Prednisone | Prednisone | 37 | 19 |
| Dimethyl Fumarate | Dimethyl Fumarate | 36 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 35 | suppressed |
| Celecoxib | Celecoxib | 35 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 35 | 12 |
| Eszopiclone | Eszopiclone | 35 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 35 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 35 | suppressed |
| Qulipta | Atogepant | 34 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 34 | suppressed |
| Zonisamide | Zonisamide | 34 | suppressed |
| Carisoprodol | Carisoprodol | 33 | suppressed |
| Dalfampridine Er | Dalfampridine | 33 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 31 | suppressed |
| Carbamazepine | Carbamazepine | 31 | suppressed |
| Xcopri | Cenobamate | 30 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 29 | suppressed |
| Ibuprofen | Ibuprofen | 29 | suppressed |
| Temazepam | Temazepam | 29 | suppressed |
| Dexamethasone | Dexamethasone | 28 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 27 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 27 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 26 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 26 | suppressed |
| Gamunex-C | Immune Globul G/Gly/Iga Avg 46 | 26 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 26 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 25 | suppressed |
| Modafinil | Modafinil | 24 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 24 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 24 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 23 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 22 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 22 | suppressed |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 21 | suppressed |
| Butorphanol Tartrate | Butorphanol Tartrate | 19 | suppressed |
| Ethosuximide | Ethosuximide | 18 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 18 | suppressed |
| Armodafinil | Armodafinil | 17 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 17 | suppressed |
| Kesimpta Pen | Ofatumumab | 17 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 17 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Ubrelvy | Ubrogepant | 17 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Copaxone | Glatiramer Acetate | 16 | suppressed |
| Diphenhydramine Hcl | Diphenhydramine Hcl | 16 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | suppressed |
| Risperidone | Risperidone | 16 | suppressed |
| Teriflunomide | Teriflunomide | 16 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 15 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 15 | suppressed |
| Neupro | Rotigotine | 15 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 15 | suppressed |
| Lamotrigine Er | Lamotrigine | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Carbatrol | Carbamazepine | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 13 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 13 | suppressed |
| Fycompa | Perampanel | 13 | suppressed |
| Geodon | Ziprasidone Hcl | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Rebif | Interferon Beta-1a/Albumin | 13 | suppressed |
| Vimpat | Lacosamide | 13 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 13 | suppressed |
| Acetazolamide | Acetazolamide | 12 | suppressed |
| Azathioprine | Azathioprine | 12 | suppressed |
| Briviact | Brivaracetam | 12 | suppressed |
| Eliquis | Apixaban | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Gammaplex | Immun Glob G(Igg)/Gly/Iga 0-50 | 12 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 12 | suppressed |
| Naratriptan Hcl | Naratriptan Hcl | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 11 | suppressed |
| Mayzent | Siponimod | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $5,352.55 · 264 records | TG Therapeutics, Inc. | AMYVID, AUSTEDO XR, Albuked, Apokyn, BOTOX, BRIUMVI, Briviact, CREXONT, EMGALITY, EPIDIOLEX, FANAPT, GAMMAKED, Gamunex-C, INGREZZA, INSPIRE, KEDRAB, KESIMPTA, KISUNLA, KOATE, LUMRYZ, Leqembi, Mavenclad, Motpoly XR, NUEDEXTA, NUPLAZID, NURTEC ODT, Nayzilam, OCTAGAM IMMUNE GLOBULIN (HUMAN), Ocrevus Zunovo, PANZYGA, PONVORY, PURIFIED CORTROPHIN GEL, QULIPTA, QUTENZA, Quzyttir, REXULTI, Radicava, RhoGAM Ultra-Filtered PLUS, Rystiggo, Sunosi, TONMYA, TRUDHESA, TYSABRI, Tyruko, UBRELVY, ULTOMIRIS, UPLIZNA, VALTOCO, VRAYLAR, VUMERITY, VYEPTI, VYVGART HYTRULO, XYWAV, Xadago, ZAVZPRET, ZEMBRACE SYMTOUCH, ZEPOSIA, ZTLido, Zilbrysq | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Botox play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error